EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients

Fanzhang Meng iD, Yuqing Zhang, Yuan Chen, Zhimin Lin, Chen Li iD, Xiujuan Hou iD, Yuanhao Wu iD

International Journal of Rheumatic Diseases · 2026-09 · 29 (9)

DOI: 10.1111/1756-185x.70825 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 28.08.2026. Verfasst von Fanzhang Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Acquired Hyperostosis Syndrome, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, Demonstration Pilot Project for the Inheritance, Innovation, and Development of Traditional Chinese Medicine in Nankai District, Tianjin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the efficacy and safety of upadacitinib administered over a short‐term period in patients with SAPHO syndrome.

Methods

In this 12‐week retrospective observational study, eligible SAPHO syndrome patients diagnosed within the past year and treated with upadacitinib were enrolled. Efficacy was assessed using the Ankylosing Spondylitis Disease Activity Score based on C‐reactive protein (ASDAS‐CRP) and the Palmoplantar Pustulosis Area and Severity Index (PPPASI). Safety was evaluated based on the incidence of adverse events during the treatment period.

Results

A total of 35 eligible patients were included. Both ASDAS‐CRP and PPPASI scores decreased rapidly by Week 4 (−1.01 and −11.41, respectively; both p < 0.001) and showed further significant improvements at Week 12 (−1.50 and −14.69, respectively; both p < 0.001) compared to baseline. Similar improvements were observed in the Visual Analogue Scale for overall musculoskeletal pain, the Bath Ankylosing Spondylitis Disease Activity Index, and other quality‐of‐life measures. Upadacitinib was well tolerated, with no serious adverse events reported. The most common adverse event was upper respiratory tract infection (20%). Other mild adverse events included elevated alanine aminotransferase, nausea, mild headache, and sore throat.

Conclusion

Upadacitinib demonstrated a rapid onset of action, significant efficacy, and a favorable safety profile in the treatment of SAPHO syndrome, supporting its potential as a therapeutic option in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingAcquired Hyperostosis SyndromeJanus Kinase InhibitorsHumansRetrospective StudiesFemaleMaleTreatment OutcomeMiddle AgedAdultTime FactorsSeverity of Illness IndexBiomarkers

Stichwörter der Autor:innen

SAPHO syndromeefficacysafetyshort‐termupadacitinib

Substanzen

Heterocyclic Compounds, 3-RingupadacitinibJanus Kinase InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Department of Rheumatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Wang Jing Hospital of CACMS, China Academy of Chinese Medical Sciences, Beijing, China.
  • Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Capital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, China.

ORCID-Profile: Fanzhang Meng, Chen Li, Xiujuan Hou, Yuanhao Wu

Förderung

  • the National Natural Science Foundation of China
  • Demonstration Pilot Project for the Inheritance, Innovation, and Development of Traditional Chinese Medicine in Nankai District, Tianjin

Zitieren

APA

Meng, F., Zhang, Y., Chen, Y., Lin, Z., Li, C., Hou, X., & Wu, Y. (2026). Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International Journal of Rheumatic Diseases, 29(9). https://doi.org/10.1111/1756-185x.70825

Vancouver

Meng F, Zhang Y, Chen Y, Lin Z, Li C, Hou X, et al. Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International Journal of Rheumatic Diseases. 2026;29(9). doi:10.1111/1756-185x.70825

BibTeX
@article{Meng2026,
  author = {Meng, Fanzhang and Zhang, Yuqing and Chen, Yuan and Lin, Zhimin and Li, Chen and Hou, Xiujuan and Wu, Yuanhao},
  title = {Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {9},
  doi = {10.1111/1756-185x.70825}
}
Kostenlos starten →